National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: Role of COX-dependent and -independent mechanisms

Neoplasia

Volumn 4, Issue 2, 2002, Pages 91-97

  Hwang, Daniel H ^a   Fung, Victor ^b,d   Dannenberg, Andrew J ^c  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chemoprevention; Cyclooxygenase; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM; CELECOXIB; CORTICOSTEROID; CYCLIC GMP PHOSPHODIESTERASE; CYTOKINE; DNA; FLUFENAMIC ACID; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 1ALPHA; MEFENAMIC ACID; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE DECARBOXYLASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN BCL XL; ROFECOXIB; SALICYLIC ACID; SULFIDE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER INHIBITION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CYTOKINE PRODUCTION; DNA BINDING; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOPREVENTION; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; UNITED STATES;

EID: 0036124654     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900226     Document Type: Conference Paper

References (45)

1. Colorectal cancer and nonsteroidal anti-inflammatory drugs
2. Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer
3. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells
4. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA
5. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas
6. The relationship between cyclooxygenase-2 expression and colorectal cancer
7. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
8. Host cyclooxygenase-2 modulates carcinoma growth
9. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models
10. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
11. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin 1: A potential mechanism for inflammatory angiogenesis
12. Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein
13. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways
14. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
15. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
16. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis
17. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin
18. Cyclic GMP mediates apoptosis induced by ulindac derivatives via activation of c-Jun NH2-terminal kinase 1
19. The anti -inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta
20. Role of BAX in the apoptotic response to anticancer agents
21. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
22. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
23. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
24. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production
25. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function
26. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production
27. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis
28. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
29. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
30. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
31. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs
32. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells
33. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
34. Differentiation and reversal of malignant changes in colon cancer through PPARγ
35. Activators of the nuclear receptor PPARgamma enhance colon polyp formation
36. Min/+ mice
37. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
38. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis
39. Intracellular unesterified arachidonic acid signals apoptosis
40. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2)
41. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
42. Aspirin-like molecules that covalently inactivate cyclooxygenase-2
43. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
44. Combinatorial chemoprevention of intestinal neoplasia